Pharma - Industrial Pharmaceutical Biotechnology - Klefenz.pdf - angielskie - MandolinkaBramborowa

Industrial Pharmaceutical Biotechnology. Heinrich Klefenz

ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)

Heinrich Klefenz

Industrial Pharmaceutical Biotechnology

Industrial Pharmaceutical Biotechnology. Heinrich Klefenz

ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)

III

Heinrich Klefenz

Industrial Pharmaceutical

Biotechnology

Industrial Pharmaceutical Biotechnology. Heinrich Klefenz

ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)

Dr. Heinrich Klefenz

Hauptstr. 35

D-76879 Bornheim

Germany

This book was carefully produced. Nevertheless, author and publisher do not warrant the informa-

tion contained therein to be free of errors. Readers are advised to keep in mind that statements, data,

illustrations, procedural details or other items may inadvertently be inaccurate.

Cover illustration: Design by ‘das trio kommunikation und marketing gmbh; Mannheim, München’

American Society for Microbiology (Tables 7.1, 7.2; ref. 502)

American Association for the Advancement of Science (Tables: 4.7, ref. 219; 5.1, ref. 224; Figures: 4.1,

ref. 154; 4.2, ref. 510; 6.1, ref. 301)

Nature Publishing Group (Fig. 1.3, ref. 432; Tables: 1.6, ref. 432; 1.7, ref. 433; 1.8, ref. 436; 1.9, ref.

437; 1.10, ref. 439).

Library of Congress Card No.: Applied for.

British Library Cataloguing-in-Publication Data:

A catalogue record for this book

is available from the British Library

Die Deutsche Bibliothek Cataloguing-in-Publication Data:

A catalogue record for this publication is available from Die Deutsche Bibliothek

ISBN 3-527-29995-5

Printed on acid-free paper.

reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated

into a machine language without written permission from the publishers. Registered names, trademarks,

etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by

law.

Composition: Manuela Treindl, Regensburg

Printing: Strauss Offsetdruck GmbH, Mörlenbach

Bookbinding: J. Schäffer GmbH & Co. KG, Grünstadt

Printed in the Federal Republic of Germany.

Industrial Pharmaceutical Biotechnology. Heinrich Klefenz

ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)

Preface

Biotechnology and its applications in medicine, pharma, and related industries represent

one of the most influential developments and pose one of the greatest challenges of the 21 st

century, both with respect to its political, societal, and ethical implications and in the search

for the fulfillment of its promises for health.

Biotechnology is stepping beyond previously insurmountable boundaries in understanding

and manipulating life, in the efforts to understand biology, to eradicate disease, to maintain

health and vigor, and to endow humans and life forms with desired properties.

This book aims to describe a fast-moving subject (or rather a whole interconnected sys-

tem of subjects) and, like in optics, some parts of the picture may be blurred and will

require further refining. It pulls together topics, which are essential for the realization of

the promises of biomedicine – the repertoire of genomics, proteomics, cytomics, bio-

informatics, and the interaction of networks – and combines with pertinent methods in

nanotechnologies, such as engineering tools to design and construct devices, artificial in-

telligence and vision processing for nano-devices, implantates, and for the envisioned swarms

of remedial nano-robots.

Crucial topics for future therapies are regenerative medicine and the cultivation of tis-

sues and organs as well as the underlying genetics and regulatory, developmental, bio-

chemical networks.

Complex traits, critical in multifactor and degenerative diseases, are being dealt with,

with a focus on senescence which forms the background against which numerous degen-

erative and acute diseases develop, the elucidation of which will facilitate the strengthening

of immune responses, the maintenance of homeostasis and biochemical networks, the pres-

ervation of the integrity of genetic and cellular structures.

Drug discovery encompasses the identification of molecular structures, the creation of

active molecules, and the development of novel comprehensive therapies like immuno-

therapy and cellular or organismal therapy with genetically engineered cells.

Biotechnology, chemistry, physics provide the tools for target identification, for the cre-

ation of new molecular structures, and for the recovery of biologically active molecules

provided by the biosphere and efficiency-honed during continuous evolutionary processes.

The huge amounts of data and information alone will not be sufficient to lead to new

molecular entities and novel therapies, since synthesizing millions of compounds will nei-

ther fill the universe of potential molecular structures nor allow the identification of those

three-dimensional structures specifically interacting with targets. The knowledge of the

biological processes and structures as the templates and targets for the identification of

active molecules is indispensable.

Biological plus chemical functional information and knowledge of interactions and net-

works will be the foundation to which the essential components of creativity and innova-

Preface

tion (and chance) are to be added as keys for the successful application of the pertinent

technologies.

The reference list of more than 700 literature citations is meant to underpin the contents

and the conclusions of the book’s theme, and to serve as a starting point for delving deeper

into individual subjects.

Special thanks go to Dr. Hovsep Sarkissian for his support in layout, in the production of

figures and tables, in proofreading and the generation of a readable manuscript. Thanks are

also due to the staff of Wiley-VCH for their organization, continuous encouragement, and

stimulation; and to the ‘Muttersprachler’ who critically read the English manuscript pro-

vided and contributed to the professionalism of the writing.

Utmost to be thankful for is the patience, understanding, and support of my family and

our two children who have tolerated extended periods of negligence.

Undoubtedly the rapid development in biotechnology, biomedicine, and supporting tech-

nologies, will affect many topics of the book’s field and will necessitate modifying, chang-

ing, or complementing the subjects.

I have no doubt that in our efforts to fulfill the potential of pharmaceutical biotechnol-

ogy, we are on a steep uphill slope and the top of the mountain (control of health, disease,

and desired properties) is in the clouds at incalculable but reachable distance.

I welcome critical comments or suggestions about the book, proposals for areas to be

dealt with in the future, and I am ready to provide further details, information, or references

about the various topics upon request.

H. Klefenz

Bornheim, December 2001

e-mail address: sarkle@t-online.de

Pharma - Industrial Pharmaceutical Biotechnology - Klefenz.pdf

Plik z chomika:

Inne pliki z tego folderu:

Inne foldery tego chomika: